Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OMP-131R10 · 1 trial · 2 indications
Subject will be assessed for DLTs during the evaluation window (28 days). Once the maximum tolerated dose (MTD) or maximum administered dose (MAD) has been determined.
| Arm | Type | Description |
|---|---|---|
| OMP-131R10 intravenous (in the vein) infusions | EXPERIMENTAL | OMP-131R10 will be administered IV on the first day of each 14-day cycle. |
| FOLFIRI (5-FU, irinotecan, leucovorin). | EXPERIMENTAL | dosing continues up to the 20 mg/kg dose level |
| Name | Type | Description |
|---|---|---|
| OMP-131R10 | DRUG | There are 5 planned dose cohorts of OMP-131R10. Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until progressive disease or unacceptable toxicity. |
| FOLFIRI | DRUG | Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen. |
Inclusion Criteria: Subjects must meet all of the following criteria to be eligible for the study: 1. Phase 1a portion: Histologically confirmed advanced relapsed or refractory solid tumors that have exhausted standard of care therapy or either refuse or are not considered to be candidates for any...
Top 20 of 45 competitors
OMP-131R10 is an investigational small molecule being developed for the treatment of advanced relapsed tumors and refractory solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
The specific molecular target of OMP-131R10 has not been disclosed in available information. The drug is being studied for its safety, pharmacokinetics, and pharmacodynamics in patients with advanced relapsed tumors.
OMP-131R10 is being developed by Mereo BioPharma Group plc, a biopharmaceutical company listed on the stock exchange under the ticker symbol MREO.
OMP-131R10 is in Phase 1 clinical development. A Phase 1a/b dose escalation study has been completed, but the drug remains investigational and is not yet approved for any use.
OMP-131R10 has one completed clinical trial, identified as NCT02482441, which was a Phase 1a/b dose escalation study evaluating the safety, pharmacokinetics, and pharmacodynamics of the drug in patients with advanced relapsed tumors and refractory solid tumors.
No alternative names for OMP-131R10 have been reported. The drug is known only by its investigational identifier OMP-131R10.